Support the news

Big Pharma And Big Prices: Biotech's Elephant In The Room13:00
Download

Play
Luxturna is a gene therapy developed by Spark Therapeutics to treat an inherited form of blindness. (Courtesy Spark Therapeutics via AP)
Luxturna is a gene therapy developed by Spark Therapeutics to treat an inherited form of blindness. (Courtesy Spark Therapeutics via AP)
This article is more than 1 year old.

The biotech boom is making way for new drug therapies to become so-called million dollar miracles, but they don't come without a price. Life-saving prescription drugs can costs hundreds of thousands of dollars — and the pharmaceutical industry spends millions on the research and development that goes into making those drugs.

There's momentum building around a new model to get drug prices to align with the benefits patients get — one that determines just how cost effective today's new drugs are.

Guests

Steve Pearson, founder and president of the Institute for Clinical and Economic Review (ICER). The institute tweets at @icer_review.

Randy Burkholder, vice president of policy and research for Pharmaceutical Research and Manufacturers of America, a trade and lobbying group. The group tweets at @PhRMA.

This segment aired on June 7, 2018.

Meghna Chakrabarti Twitter Host, On Point
Meghna Chakrabarti is the host of On Point.

More…

Paris Alston Twitter Producer, Radio Boston
Paris is an associate producer for Radio Boston.

More…

+Join the discussion
TwitterfacebookEmail

Support the news